secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001104659-25-046124
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q1 2025 revenue $18.5M (+12% YoY); net loss $11.3M; reiterates FY revenue guidance $85-88M
--------------------------------------------------------------------------------

- Revenue $18.5M, up 12% YoY; OviTex +15%, OviTex PRS +2%.
- Net loss $11.3M vs $5.7M; operating loss $10.5M (prior-year included $7.6M asset sale gain).
- Cash $42.8M; reiterates FY2025 revenue guidance $85-88M (23-27% growth), opEx flat YoY.
- Full U.S. launch of larger OviTex PRS for plastic/reconstructive surgery commenced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925046124/0001104659-25-046124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925046124/tm2514412d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-046124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer